Concerns surround use of direct-to-consumer genetic testing

Concerns surround use of direct-to-consumer genetic testing

(HealthDay)—Direct-to-consumer genetic testing raises unique concerns and considerations, according to a committee opinion published online Oct. 24 in Obstetrics & Gynecology.

Britton Rink, M.D., and colleagues, in collaboration with the American College of Obstetricians and Gynecologists' Committee on Genetics, discussed direct-to-consumer genetic testing. The authors note that many genetic companies have started marketing directly to consumers and that direct-to-consumer testing raises unique concerns and considerations, including lack of knowledge among patients and about available tests, difficulty in interpretation of test results, lack of oversight of companies offering genetic testing, and issues relating to privacy and confidentiality.

The authors write that an obstetrician-gynecologist or other health care provider with knowledge of genetics should be involved in ordering and interpreting results of any genetic test with medical implications because of the complexities involved. When test results from direct-to-consumer genomic testing that assess the risk of specific diseases are presented to a health care provider, the patient should be referred to a health care provider who is skilled in risk assessment for the diseases of interest as well as in the interpretation of these results in the context of relevant medical and family history.

"Because of these considerations and in view of the fact that the of the results requires specific training and medical knowledge, direct-to-consumer genetic testing should be discouraged because of the potential harm of a misinterpreted or inaccurate result," the authors write.

Explore further

The benefits and dangers when genetic testing companies partner with orphan drug developers

More information: Abstract/Full Text (subscription or payment may be required)
Journal information: Obstetrics & Gynecology

Copyright © 2017 HealthDay. All rights reserved.

Citation: Concerns surround use of direct-to-consumer genetic testing (2017, October 27) retrieved 17 October 2019 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments

Oct 27, 2017
Well I think the major concern is that if someone like 23andme provides you with your exome for a few hundred dollars -- then the medical industry can't unpack all the different genes and offer tests costing thousands of dollars for each indication. The individual should own his genome and should have the right to know what it is -- without the medical industry skimming off hundreds of thousands of dollars. Yes, there are some risks, but life itself is risky. It is also risky when the individual needs the information but can't afford to pay the money that monopolist in the genetic medical industry are seeking.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more